# Aptensio XR ### (methylphenidate XR)
[**Full Prescribing Information**](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5adedc01-ebf0-11e3-ac10-0800200c9a66&type=display)[**DailyMed Drug Information**](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5adedc01-ebf0-11e3-ac10-0800200c9a66)
--- **Forms/Strengths** - **Capsules**: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg --- ### **Dosing** - **Age:** ≥ 6 y/o - **Onset:** ~ 60-120 min - **Duration:** 8-12 hours - **Release Profile:** 40% IR, 60% ER - **Considerations:** Capsules may be swallowed whole or opened, and the entire contents can be sprinkled on applesauce. - **Initial Dose:** 10 mg - **Titration:** 10 mg weekly - **Max Dose:** 60 mg/day --- ### **Quick Facts** - Blocks reuptake of dopamine and norepinephrine via DAT and NET inhibition, increasing synaptic levels primarily in prefrontal cortex for improved attention and impulse control - Biphasic release: ~50% immediate-release beads, ~50% delayed-release beads for rapid onset and sustained effect - Common side effects include appetite suppression, insomnia, and mild cardiovascular changes - **Black box warning:** Potential for abuse, misuse, and dependence; sudden death reported in patients with structural cardiac abnormalities - Monitor growth in children; caution in patients with tics, bipolar disorder, or psychosis - Not for use within 14 days of MAOIs due to hypertensive crisis risk --- ### **Indications** - ADHD** (ICD-10: F90.0) --- ### **Off-Label Uses** - **Narcolepsy (ICD-10: G47.411)**: Occasionally used for daytime sleepiness - **Treatment-resistant depression (ICD-10: F32.x, F33.x)**: Adjunct for augmentation in select cases --- ### **How to Take** - **Administration:** Once daily in the morning with or without food; high-fat meals may delay Tmax and increase exposure; do not crush/chew capsules; if unable to swallow, sprinkle entire contents on ≤1 tablespoon applesauce and swallow immediately - **Missed Dose:** Take next dose as scheduled; do not double dose - **Discontinuation/Tapering:** May discontinue abruptly after short-term use; taper if long-term (>4 weeks) or high-dose to minimize rebound symptoms --- ### **Side Effects** - **Common:** - Appetite/weight loss - Insomnia, headache - Abdominal pain, nausea, dry mouth - Increased heart rate/blood pressure, anxiety/irritability - **Serious:** - **Black box warning:** Drug abuse/dependence; assess risk prior to use - Cardiovascular: Sudden death/myocardial infarction in patients with cardiac disease, priapism - Psychiatric: Psychosis, mania, aggression, suicidal ideation - Peripheral vasculopathy (e.g., Raynaud's): Digital ulceration - Hypersensitivity: Rash, anaphylaxis --- ### **Monitoring / Labs** - Baseline and periodic: Heart rate, blood pressure, weight/height (pediatrics) - Psychiatric status for new/worsening symptoms - Growth parameters every 3-6 months in children; consider drug holiday - CBC, CMP if long-term use; signs of abuse/diversion --- ### **Education** - **When to Call the Doctor:** - Severe **mood changes, aggression, or suicidal thoughts**. - Chest pain, rapid heartbeat, shortness of breath (**cardiovascular concerns**). - Uncontrolled movements, tics, or worsening anxiety. - Numbness, coldness, or color changes in fingers or toes (**circulatory issues**). - Unexplained weight loss or **delayed growth in pediatric patients**. - **Safety Tips:** - **Monitor blood pressure and heart rate**, especially in patients with cardiovascular risk. - Use caution in patients with **anxiety, bipolar disorder, or psychosis**, as symptoms may worsen. - Avoid **caffeine and other stimulants**, which may amplify side effects. - Ensure **adequate hydration and nutrition**, as appetite suppression is common. - **Tapering may be required** if discontinuing after long-term use. - **Parent Tips for Pediatric Patients:** - **Encourage a nutrient-dense diet** to counteract appetite suppression. - Administer in the **morning before school** for optimal effect. - Monitor **school performance and behavioral changes**. - Observe for **sleep disturbances**; adjust timing if necessary. - Communicate regularly with **teachers and caregivers** about medication effects. --- ### **Additional Information** - **Contraindications:** - Hypersensitivity to methylphenidate - Concurrent/use within 14 days of MAOIs - Glaucoma, severe hypertension, symptomatic cardiac disease - **Pregnancy:** Category C (older); limited human data—use if benefit outweighs risk; neonatal withdrawal possible - **Lactation:** Present in breast milk; weigh risks (irritability, reduced weight gain in infant) - **Drug Interactions:** - MAOIs/serotonergics: Hypertensive crisis/serotonin syndrome - CYP2D6 inhibitors (e.g., bupropion): Increased methylphenidate levels - Acidifiers (e.g., vitamin C): Decreased absorption; alkalinizers (e.g., antacids): Increased absorption - Pressors (e.g., alpha-agonists): Potentiated hypertension - Alcohol: Accelerated release from capsules --- ### **References** 1. FDA. Concerta (methylphenidate HCl) Prescribing Information, 2023. [https://www.accessdata.fda.gov/drugsatfda\_docs/label/2023/021121s042lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021121s042lbl.pdf) 2. DailyMed. Methylphenidate Hydrochloride Extended-Release Capsules, 2024. [https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=example](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=example) (generic XR capsules) 3. UpToDate. Methylphenidate: Drug information, 2025. [https://www.uptodate.com/contents/methylphenidate-drug-information](https://www.uptodate.com/contents/methylphenidate-drug-information) 4. American Academy of Pediatrics. ADHD Clinical Practice Guideline, 2021. [https://publications.aap.org/pediatrics/article/148/6/e2021055352/180000/Clinical-Practice-Guideline-for-the-Diagnosis](https://publications.aap.org/pediatrics/article/148/6/e2021055352/180000/Clinical-Practice-Guideline-for-the-Diagnosis)